Skip to main content

Advertisement

Table 2 Indirect effects, immunogenicity, and indirect effect adjustments for PCV7, PCV10, and PCV13

From: Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada

  Bacteremia Meningitis Inpatient PNE Outpatient PNE Mild AOM Moderate/Severe AOM Source(s)/ Assumption
Indirect effects (years)        
  PCV7        
    0–2 0.68 0.68 0.07 0.16 0.21 0.15 [40, 42, 44, 65]
    3–4 0.68 0.68 0.00 0.00 0.00 0.00
    5–17 0.39 0.39 0.00 0.00 0.00 0.00
    18–64 0.47 0.47 0.26 0.00 0.00 0.00
    64+ 0.36 0.36 0.00 0.00 0.00 0.00  
PCV10 (for Sensitivity analysis)a,b        
    0–2 0.41 0.41 0.04 0.10 0.13 0.09  
    3–4 0.43 0.43 0.00 0.00 0.00 0.00
    5–17 0.26 0.26 0.00 0.00 0.00 0.00
    18–64 0.39 0.39 0.22 0.00 0.00 0.00
    64+ 0.28 0.28 0.00 0.00 0.00 0.00  
PCV131        
    0–2 0.59 0.59 0.06 0.14 0.18 0.13  
    3–4 0.62 0.62 0.00 0.00 0.00 0.00
    5–17 0.30 0.30 0.00 0.00 0.00 0.00
    18–64 0.55 0.55 0.30 0.00 0.00 0.00
    64+ 0.42 0.42 0.00 0.00 0.00 0.00  
Immuno-genicity for PCV10 Direct Effects 0.90 0.90 0.85 0.80 0.75 0.75 [36]
  1. AOM acute otitis media; PCV7 7-valent pneumococcal polysaccharide-protein conjugate vaccine; PCV10 10-valent pneumococcal conjugate vaccine; PCV13 13-valent pneumococcal conjugate vaccine; PNE pneumonia.
  2. a Adjusted for serotype coverage and year of coverage.
  3. b Indirect effects for PCV10 are assumed to be 0 in the base case.